IDXG (Interpace Biosciences) Other Current Assets: $0.88 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDXG Interpace Biosciences Inc IDXG
41 GF Score
Price $1.61
GF Value $0.20
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Interpace Biosciences Other Current Assets?

Interpace Biosciences IDXG +2.55% 41 Other Current Assets is $0.88 Mil as of Jun. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Interpace Biosciences's other current assets for the quarter that ended in Jun. 2026 was $0.88 Mil.

Interpace Biosciences's quarterly other current assets declined from Dec. 2025 ($0.63 Mil) to Mar. 2026 ($0.43 Mil) but then increased from Mar. 2026 ($0.43 Mil) to Jun. 2026 ($0.88Mil).

Interpace Biosciences's annual other current assets declined from Dec. 2023 ($0.61 Mil) to Dec. 2024 ($0.56 Mil) increased from Dec. 2024 ($0.56 Mil) to Dec. 2025 ($0.63 Mil).


Interpace Biosciences Other Current Assets Related Terms


Interpace Biosciences Other Current Assets Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Other Current Assets Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 1.07 0.61 0.56 0.63

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.64 0.63 0.43 0.88
IDXG
41GF Score
Interpace Biosciences Inc IDXG
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.88 Mil mean?
Interpace Biosciences (IDXG) has a Other Current Assets of $0.88 Mil as of Jun. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Interpace Biosciences.
Is Interpace Biosciences' Other Current Assets too high?
Interpace Biosciences' current Other Current Assets is $0.88 Mil. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Other Current Assets compare to PRPO and ADVB?
Interpace Biosciences' Other Current Assets of $0.88 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Medical Diagnostics & Research company?
A good Other Current Assets depends on the Medical Diagnostics & Research industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Interpace Biosciences. Interpace Biosciences's current Other Current Assets is $0.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current Other Current Assets is $0.88 Mil. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Other Current Assets is $0.88 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (IDXG) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20. GuruFocus considers Interpace Biosciences to be Significantly Overvalued.

Key valuation signals for IDXG:

  • Other Current Assets: $0.88 Mil
  • GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Interpace Biosciences Business Description

Other Exchanges PF42:Germany
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for IDXG

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.61
Price
$0.20
GF Value